uniQure (NASDAQ:QURE) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 8,232 call options on the company. This is an increase of approximately 891% compared to the average volume of 831 call options.
Several brokerages have recently commented on QURE. Mizuho upgraded uniQure from a “neutral” rating to a “buy” rating and set a $52.00 price objective on the stock in a research report on Thursday, April 1st. Zacks Investment Research cut shares of uniQure from a “hold” rating to a “sell” rating in a report on Tuesday, March 16th. Guggenheim raised uniQure from a “neutral” rating to a “buy” rating and set a $62.00 target price on the stock in a research note on Thursday, January 7th. Chardan Capital upped their price objective on shares of uniQure from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, March 8th. Finally, Royal Bank of Canada boosted their target price on shares of uniQure from $53.00 to $61.00 and gave the company an “outperform” rating in a report on Tuesday, December 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $67.29.
Shares of uniQure stock opened at $32.51 on Wednesday. The firm’s 50-day moving average is $33.44 and its two-hundred day moving average is $38.66. uniQure has a 1 year low of $28.58 and a 1 year high of $71.45. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -8.62 and a beta of 1.19. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.62 and a quick ratio of 8.62.
In related news, CAO Christian Klemt sold 952 shares of uniQure stock in a transaction on Tuesday, January 26th. The stock was sold at an average price of $39.00, for a total transaction of $37,128.00. Following the completion of the sale, the chief accounting officer now owns 56,066 shares of the company’s stock, valued at $2,186,574. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Alexander Edward Kuta III sold 6,000 shares of the business’s stock in a transaction dated Thursday, April 15th. The stock was sold at an average price of $35.06, for a total value of $210,360.00. Following the transaction, the vice president now owns 74,871 shares of the company’s stock, valued at $2,624,977.26. The disclosure for this sale can be found here. Insiders have sold a total of 42,018 shares of company stock worth $1,527,331 in the last three months. Insiders own 2.79% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Penserra Capital Management LLC grew its holdings in uniQure by 171.2% in the fourth quarter. Penserra Capital Management LLC now owns 1,025 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 647 shares during the period. Advisory Services Network LLC purchased a new stake in shares of uniQure in the fourth quarter valued at approximately $38,000. RMR Wealth Builders purchased a new position in shares of uniQure during the 4th quarter worth $50,000. Pacer Advisors Inc. acquired a new stake in shares of uniQure during the 4th quarter worth approximately $75,000. Finally, Exane Derivatives purchased a new stake in shares of uniQure during the 4th quarter valued at approximately $85,000. 78.34% of the stock is owned by hedge funds and other institutional investors.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3.
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.